Olaparib Plus Ceralasertib in Metastatic Triple-Negative Breast Cancer: VIOLETTE Trial
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
At the ESMO Breast Cancer Congress held in Berlin from May 3 to 5, 2022, results were presented for the VIOLETTE Phase 2 clinical trial. This study investigated the efficacy and safety of combining Olaparib (a PARP inhibitor) with Ceralasertib (an ATR inhibitor) in patients with previously treated metastatic triple-negative breast cancer (TNBC).
Study Design: VIOLETTE Trial
The VIOLETTE trial randomized patients with metastatic TNBC who had failed at least one prior line of therapy into two main arms:
- Olaparib Monotherapy
- Olaparib + Ceralasertib Combination
The primary endpoint was progression-free survival (PFS).
Key Results
The study results showed a modest numerical improvement in PFS with the combination, but the overall benefit remained limited:
- Median PFS: 5.3 months for the Olaparib + Ceralasertib group vs. 3.6 months for the Olaparib monotherapy group.
- Objective Response Rate (ORR):
- BRCA Mutation Patients: 50.0% (Combination) vs. 44.2% (Monotherapy).
- HRR Mutation Patients: 20.0% (Combination) vs. 15.0% (Monotherapy).
- Non-HRR Mutation Patients: 15.4% (Combination) vs. 3.9% (Monotherapy).
While the combination showed some activity in patients without homologous recombination repair (HRR) mutations, it did not provide a significant clinical breakthrough for the broader population.
Safety Profile
Common adverse events included anemia and neutropenia. Grade 3 or higher adverse events occurred in 46.8% of patients in the combination group compared to 35.5% in the monotherapy group.
Conclusion
Dr. Suzette Delaloge from Institut Gustave Roussy noted that while basic research suggested synergy between PARP and ATR inhibition, the VIOLETTE trial did not demonstrate a substantial clinical benefit for pre-treated metastatic TNBC patients with BRCA mutations. However, the signals observed in patients without HRR mutations suggest that ATR inhibition may have independent antitumor activity worth further exploration.
Source: ESMO Daily Reporter - VIOLETTE Trial Highlights
#BreastCancer #TNBC #Olaparib #Ceralasertib #PARPInhibitor #ATRInhibitor #CancerResearch
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4